The standard linear-quadratic survival model for radiotherapy is used to investigate different schedules of radiation treatment planning to study how these may be affected by different tumour repopulation kinetics between treatments. The laws for tumour cell repopulation include the logistic and Gompertz models and this extends the work of Wheldon et al (1977 Br. J. Radiol. 50 681), which was concerned with the case of exponential re-growth between treatments. Here we also consider the restricted exponential model. This has been successfully used by Panetta and Adam (1995 Math. Comput. Modelling 22 67) in the case of chemotherapy treatment planning.Treatment schedules investigated include standard fractionation of daily treatments, weekday treatments, accelerated fractionation, optimized uniform schedules and variation of the dosage and α/β ratio, where α and β are radiobiological parameters for the tumour tissue concerned. Parameters for these treatment strategies are extracted from the literature on advanced head and neck cancer, prostate cancer, as well as radiosensitive parameters. Standardized treatment protocols are also considered. Calculations based on the present analysis indicate that even with growth laws scaled to mimic initial growth, such that growth mechanisms are comparable, variation in survival fraction to orders of magnitude emerged. Calculations show that the logistic and exponential models yield similar results in tumour eradication. By comparison the Gompertz model calculations indicate that tumours described by this law result in a significantly poorer prognosis for tumour eradication than either the exponential or logistic models. The present study also shows that the faster the tumour growth rate and the higher the repair capacity of the cell line, the greater the variation in outcome of the survival fraction. Gaps in treatment, planned or unplanned,
also accentuate the differences of the survival fraction given alternative growth dynamics.
(Some figures in this article are in colour only in the electronic version)
Introduction and background
Radiotherapy has long been in use to treat cancer, and is still a major weapon within the oncologist's arsenal, being second only to surgery, as well as being an adjunct to surgery or chemotherapy. Over half of all cancer patients receive radiotherapy at some stage of their disease, with an increasing proportion achieving long-term cure (Kaanders et al 2002 , Demanes et al 2005 , Song et al 2006 . Over the last 50 years, significant progress has been made by radiobiologists in understanding the mechanisms of how radiation results in DNA damage. The linear-quadratic (LQ) model has been a useful tool for understanding the radiation survival response for a solid tumour (Fowler 2006) and has gained relatively widespread acceptance among radiobiologists and clinicians (Fowler and Stern 1960 , Withers et al 1983 , Dale 1996 , Sachs and Brenner 1998 , Wheldon et al 1998 , Jones and Dale 1999 , Sachs et al 2001 . It states that for external beam radiotherapy, the clonogenic surviving fraction σ is given by
where D (Gy) is a single radiation dose and α (Gy −1 ) and β (Gy −2 ) are the radiobiological cell survival parameters dependent on tissue type within the volume being treated. These parameters are biologically interpreted as single and double track events resulting in sublethal and lethal breaks in the DNA helix, respectively (Sachs et al 1997, Chadwick and Leenhouts 1973) . The ratio (α/β) is an inverse measure of a tissue's sensitivity to fractionation, that is, the size of dose given on each treatment. For example, typical values for α/β range from 3-10 Gy (Wheldon et al 1998 , Dale 1996 , Thames et al 1990 . In fact, the ratio α/β can be as low as 1 Gy in the case of prostate cancer (Carlson et al 2004 , King et al 2000 and as high as 20 Gy in the case of advanced head and neck cancer (Steel 2002 , Thames et al 1990 .
This typical range in values corresponds respectively to late responding tissue for low α/β values, which has a high repair capacity, through to acute responding tissue for high α/β values which has a low repair capacity. Acute responding tissues have fast cellular turnover and therefore show signs of radiation induced damage to normal tissue days to weeks after exposure. This can be explained due to the short lifespan of their mature cells. By comparison late responding tissues show effects months to years later because they have a low level of cellular turnover and the interval between cell divisions is long giving the cells an opportunity to repair radiobiological damage (Hall and Giaccia 2006) . Fraction size is a dominant feature in determining late effects with overall treatment time having little influence. In contrast, the response by acute responding tissue is influenced by (i) fractionation, but to a lesser degree, and (ii) the overall treatment time (Hall and Giaccia 2006) .
Advances in the treatment schedules have resulted from taking account of the particular radiobiological cell survival parameters (α/β) involved. The conventional treatment is 30 fractions of 2 Gy given one fraction per day, 5 days a week. Other treatments now include hyper-fractionation, hypo-fractionation, accelerated fractionation, CHART (continuous hyperfractionated accelerated radiotherapy), ARCON (accelerated hyperfractionated radiation therapy with carbogen and nicotinamide) and SMART (simultaneous modulated accelerated radiation therapy) (Hall and Giaccia 2006 , Steel 2002 , Butler et al 1999 . For instance, hyperfractionation is the division of the total conventional dose of radiation into smaller doses usually given more than once a day. This exploits a cell line with a high α/β value as it is relatively insensitive to changes in fraction size, and this reduces late effects with only a slight increase in early effects. On the other hand, accelerated fractionation involves the reduction in overall treatment time whilst maintaining the total dose received and is therefore suited to cell lines with a low α/β value. It is intended to reduce repopulation in rapidly proliferating tumours, but as the number and dose per fraction is unaltered, late effects are unchanged.
Quantitative radiobiological modelling using the LQ model has been carried out for targeted intraoperative radiotherapy (Enderling et al 2006) and extracranial stereotactic radiosurgery (ESR) (Guerrero and Li 2004) . The significance of heterogeneity of the tumour within radiotherapy to examine the role of hypoxia and reoxygenation has also been studied (Buffa et al 2001, Jones and Dale 1999) . Webb and Nahum (1993) considered the inhomogeneous distribution of dose and clonogenic cell density, Suwinski et al (1999) the heterogeneity of tumour cell kinetics, whilst Brenner et al (1995) extended the LQ model to include redistribution and re-oxygenation. The LQ model has also been incorporated into 4D simulation models for tumour response to radiotherapy in vivo (Antipas et al 2004 , and more recently Dawson and Hillen (2006) have considered extensions to include the cell cycle dynamics.
For rapidly proliferating tumours, repopulation is a major factor in the response to irradiation. Fractionation allows not only the tumour to repopulate but also for the normal tissue to recover. Typically, the tumour sensitivity and repopulation are considered to be constant during radiotherapy. However, it has been suggested by Ribba et al 2006 (and references therein) that cell cycle regulation and anti-growth signals such as hypoxia (Gray et al 1953) can play an important role in the reduction in response to radiation. That is, for those cells within the S-phase of the cell cycle, or given low levels of oxygenation, a higher level of radio-resistance occurs. As a tumour shrinks during the course of treatment, those cells within the S-phase may well have moved to a less radio-resistant phase, and diffusion-limited hypoxia decreases due to re-oxygenation. Nutrient deprived cells are less apt at mitosis, therefore, as the tumour shrinks and re-oxygenation occurs to areas previously deprived, the net repopulation rate will increase (Fowler 1991 , Sham and Durand 1998 , Wein et al 2000 . This indicates a repopulation rate that is not constant throughout the course of therapy, but one that is dependent on the size and population of the tumour. One example of this may be found in some human lung cancers which have been shown by Steel (1977 Steel ( , 2002 to follow a Gompertzian pattern of growth. It has been shown that larger tumours have longer volume doubling times than smaller ones (Steel 1977 , Spratt et al 1993 . It is known that the five R's of radiotherapy exist, the four R's of repair, redistribution, re-oxygenation and repopulation noted by Withers in 1975, and radiosensitivity (Steel et al 1989) . All factors play an important role, but none more so than repopulation.
Previous studies have considered fractionated radiotherapy with growth kinetics. In 1976 Wheldon and Kirk established that given exponential growth of the surviving clonogenic cells, the uniform treatment schedules of 2 Gy given daily for 30 consecutive treatments could be improved upon given the knowledge of the tumour volume doubling time t 2 . They initially considered the multi-target survival equation for a 'shouldered' survival curve, before extending the method to the LQ form of the survival fraction equation (1). In 1980, Usher calculated the optimal uniform treatment schedule for the LQ model, 'shoulderless' and 'shouldered' form of the multi-target survival equation given exponential re-growth. However, Usher only presented results for Gompertz growth kinetics given a 'shouldered' multi-target survival equation. Later on, non-constant growth kinetics was recognized as worth consideration by O'Donoghue (1997) where tumour cell proliferation was modelled as exponential at small tumour sizes and Gompertzian at larger sizes and integrated into the LQ description of tumour sterilization. More recently, other considerations for fractionated radiotherapy have been given attention, such as the effect of delay on tumour repopulation during treatment (Armpilia et al 2004) .
In this paper the role of various nonlinear growth laws, which describe non-constant growth of a tumour, are considered along with the impact that they will have on the outcome given various fractionated treatment schedules. The models that we investigate include the restricted exponential (after Panetta and Adam (1995) ), the logistic and Gompertz models, and are compared with the assumed constant growth kinetics given by the exponential model.
Growth mechanisms and the LQ model
In radiotherapy, treatment schedules are fractionated to allow the normal tissue to repair and recover from the irradiation. During these periods of recovery and resting, surviving clonogenic cells of the tumour also repair and repopulate. The nature of the re-growth of the particular tumour concerned is expected to influence the outcome of a specific treatment schedule. We now investigate different repopulation laws for tumour cell lines and study what implications they may have in the clinical radiation treatment planning of cancer.
A general formulation for the repopulation of a homogeneous tumour cell line during radiation treatment is,
. . .
where N i is the resulting number of clonogenic cells after the ith time interval, t, in which the tumour has grown and been irradiated, σ is the clonogenic survival fraction of the tumour as given by equation (1) and the function f (N i , t) represents one of the following growth mechanisms:
(i) exponential model;
(ii) logistic model; (iii) Gompertz model; (iv) restricted exponential model.
The model assumes implicitly that the time taken to give treatment is negligible in comparison to the time interval t between treatments. Furthermore, if a cell is no longer able to proliferate due to irradiation damage, it is assumed dead with immediate effect. Biologically however, it should be appreciated that this damage takes a finite amount of time to filter through the cell cycle and only upon the onset of mitosis does the damage become apparent. The model also allows for the fact that some DNA damage of the tumour cells can be repaired before cell division. This repair factor is taken account of by the β component of σ (equation (1)). This means a high α/β ratio signifies a tumour cell line with a low repair capacity and vice versa (Wheldon 1988) . Given this simplified view of the tumour structure, equation (2d) is incorporated into the growth laws described in section 2.1. In section 2.1 and thereafter we use the subscripts e, r, l and g as notational markers to identify the exponential, restricted exponential, logistic and Gompertz models, respectively.
Growth laws
Exponential growth is modelled by the equation,
where g e = ln 2/t 2 is the constant growth rate determined by relating it to the tumour doubling time t 2 and N 0 is the initial number of cells at t = 0 from which growth is considered to evolve for a period of time t. Here, f e (N i , t) = N i exp(g e t), where N i is the number of cells after the ith time interval of growth and irradiation. After n uniform scheduled treatments at time intervals t, the survival fraction is
where a e = exp(−g e t) and n,e = N n /N 0 is the relative number of cells surviving the treatment schedule (or the surviving fraction) as given by Wheldon and Kirk in 1976. A simple extension of the exponential growth law is that of the restricted exponential growth mechanism (Panetta and Adams 1995) . This model, unlike the exponential model, is able to account for the decrease in clonogenic cell rate as the tumour grows. It may be written in the form
where K is the carrying capacity or limiting size the tumour would reach without treatment or death and N 0 is the initial number of cells at t = 0 from which growth is considered to evolve for a period of time t. The parameter g r is the growth rate of the clonogenic cells and may be related to the growth rate of the exponential model according to Figure 1 illustrates the scaling of the various growth mechanisms for the case of t 2 = 60 days, N 0 = 0.1K and K = 1. Note that with this appropriate scaling, the growth kinetics of the exponential and restricted exponential models are comparable for almost 50 days before and after the point of reference, N 0 , for scaling. N 0 is also taken to be the size of the tumour when the treatment schedule begins. Thus, for the case of the restricted exponential model the
and the final survival fraction at the end of n treatments at time intervals t is obtained from equation (2d). Evaluating this gives
where a r = exp(−g r t). It should be noted that n is no longer independent of N 0 and also incorporates the carrying capacity K. Therefore an estimation of N 0 relative to K is taken, for instance K = 10N 0 or K = 2N 0 when considering a smaller or larger tumour volume respectively at the commencement of treatment. This additional knowledge is required in the case of any limited growth model. (3), (6), (11) and (16). Part (b) depicts N versus time given by equations (4), (7), (12) and (17). Note that the exponential and restricted exponential growth mechanisms are linear in terms of N whilst logistic and Gompertzian growth mechanisms are nonlinear.
Another form of self-limiting growth is the logistic model,
where N 0 is the initial number of cells at t = 0 from which growth is considered to evolve for a period of time t. g l is the non-constant growth rate associated with logistic growth, which may be scaled to the growth rate in the exponential case at N 0 via the relation
Again this is illustrated in figure 1 , where one can see that the logistic model follows similar dynamics to that of the exponential model. It is only after approximately 100 days, for the given parameters, that the limiting behaviour of the logistic growth begins to show and deviation away from the constant growth rate of the exponential growth occurs. For the logistic growth model, the general form of f (N i , t) is given by
and so the number of clonogenic tumour cells surviving n treatments may be obtained from equation (2d) to yield
where now a l = exp(−g l t). Von Bertalanffy generalized the logistic model to represent an alternative growth law for avascular tumour growth. He suggested that dN dt
where γ, δ, λ and µ are positive parameters with µ > λ. By taking µ = 1 (assuming decay is proportional to size),
where the growth rate is scaled accordingly by g g = g e /ln(K/N 0 ) and N 0 is the initial number of cells at t = 0 from which growth is considered to evolve for a period of time t. The scaling of the Gompertz kinetics to that of the exponential model, at the initial stage N 0 , is depicted in figure 1 . For the Gompertz model the general form of f (N i , t) is given by
The nth survival fraction after treatment obtained from equation (2d) is
where a g = exp(−g g t).
Equations equations (5), (10), (14) and (19) are the analytical outcome for the surviving clonogenic cells after n treatments, each at uniform time intervals t, allowing for repopulation. Due to the uniformity of all n treatments, an optimum uniform treatment schedule can be calculated, as detailed by Wheldon et al in 1977 for exponential re-growth. The design of an optimum treatment strategy requires minimizing both the survival fraction and damage to normal connective tissue through selection of the number of fractions n, the uniform time interval t and the dose D. The parameter n is obtained from the power-function representation,
, where a = 0.65, b = 0.11 are best fit parameters to clinical data for connective tissue for the cumulative radiation effect (CRE) for x-rays (Kirk et al 1971 , Wheldon et al 1977 , Hamlet et al 1980 , Usher 1980 . The quantity tol in the power function model denotes a tolerance to damage of normal tissue from radiation. The CRE is an isoeffect model and provides a scale of the radiobiological damage (Wheldon 1988) . Due to the tractable analytical form of equation (5), Wheldon et al (1977) (10), (14) and (19), the same procedure can be carried out, however it is algebraically messy, involving more parameters. Moreover, given that the dynamics of the logistic and Gompertz models are not constant, as in the case of the exponential model, but dependent on N, it then follows that the optimum dose D * and time interval t * are themselves non-constant throughout the treatment schedule. This situation is due to the changing tumour size N throughout the treatment, and therefore parameters that are optimum at one stage, may not be optimum at another. An analytical expression for the optimized dose and interval of time between treatments for a uniform treatment schedule is not presented here. However, in view that treatment schedules are usually no longer uniform, numerical calculations have been obtained to observe the possible differences in the final outcome with these four growth laws, given the same initial conditions of clonogenic cells N 0 and an estimation of the growth rate g e , obtained in the usual fashion if exponential growth were assumed (i.e. from the deduction of t 2 ). In section 2.2 the case of limiting uniform treatments is considered. Observing how n,i (i = e, r, l, g ) behaves as n → ∞ (and so total time T = nt → ∞), gives an indication of the likely effects that the various growth laws have upon the resulting outcomes and whether any inconsistencies exist.
Limits within uniform treatment schedules
Letting n → ∞, then the survival fraction from irradiation and the four possible mechanisms of tumour re-growth will tend to the following values:
where the last relationship holds when exp[ln(σ )/(1 − a g )] K/N 0 . Of particular note is the limiting behaviour of the restricted exponential growth model. Here equation (20b) indicates that a ceiling is reached for the number of clonogenic cells that may be eradicated irrespective of the length of the uniform treatment schedule. The discrepancy between this mechanism and the other three can be explained by looking at dN/dt, the rate of growth of the tumour. In the case of exponential growth, the rate of change in N (as given by equation (3)) is a positive linear curve, but for logistic equation (11) and Gompertz equation (16) growth, this rate is nonlinear in N, it being initially positive, obtaining a maximum positive value and decreasing back to zero as N approaches its carrying capacity K. In contrast, for restricted exponential growth, the rate of change of N, (dN/dt), is continually decreasing in a linear sense with changing value of N, i.e. dN/dt versus N has a negative gradient. That is, as N is decreased by irradiation, the rate of re-growth is (i) decreasing constantly for the case of exponential re-population, (ii) ultimately decreased in the case of logistic and Gompertz growth since there are fewer clonogenic cells to repopulate and (iii) increased in the case of the restricted exponential growth law. This can be seen in figure 1(a) .
All rates of change of N are the same at the initial tumour size N 0 at which treatment begins via the scaling of the growth rates g i (i = e, r, l, g ). The continual negative gradient of dN/dt versus N, in the case of the restricted exponential re-growth, may explain the lack of success at tumour regression. Here, as treatment proceeds, the rate of repopulation increases until the situation is such that the decrease in N from irradiation is equal to the re-growth of N and thus an impasse is reached which cannot be easily overcome. This can be seen in figure 1(a) and illustrates the importance of the choice of model for the tumour kinetics as to the calculated outcome. Therefore, in the following analysis, the results from the restricted exponential case will not be commented on.
Treatment schedules: results and discussion
The growth from each model has been appropriately scaled so that the same initial conditions exist. This is shown in figure 1(b) . It is only as the tumour proliferates between treatments that the difference from the various growth mechanisms become apparent. The ratio of α/β, N 0 /K, and the value of the dose D and the treatment schedule have all been varied with results presented in tables 1-5. Tabulated are the values of the survival fraction (SF) at the end of the various treatment schedules and parameters. Figure 2 is an illustrative example of the evolution of the relative size of the tumour throughout the treatment schedule given the four possible models for the re-growth mechanism. All four re-growth mechanisms are illustrated, but only exponential, logistic and Gompertz models will be commented on due to the reasons 3.349 × 10 −5 0.5 5.247 × 10 −6 1.081 × 10 −5 6.733 × 10 −4 60 0.1 3.532 × 10 −6 3.678 × 10 −6 9.717 × 10 −6 0.5 3.532 × 10 −6 5.077 × 10 −6 6.831 × 10 −5 90 0.1 3.096 × 10 −6 3.180 × 10 −6 6.202 × 10 −6 0.5 3.096 × 10 −6 3.944 × 10 −6 2.573 × 10 −5
The values used are α/β = 20 Gy, t 2 = 30 days, N 0 /K = 0.5. Such a parameter choice would be appropriate for a fast proliferating, advanced head and neck tumour that has already reached a significant size before treatment begins. Again, the repopulation of the tumour can be seen over the weekend period. The results depicted are not intuitive on first inspection since the SF with exponential growth kinetics, which is constant in its growth rate (as seen in figure 1) , is minimized the most by the irradiation treatment rather than the other forms of growth which are limited. This can be explained by the fact that though the exponential growth rate is constant, and does indeed exceed that of the other three limited growth mechanisms if the tumour were allowed to grow uninterrupted ( figure 1(b) ), as treatment occurs, the tumour shrinks and so N is decreasing and thus dN/dt is altered. As illustrated in figure 1(a) , dN/dt is dependent on N in the case of logistic and Gompertz dynamics, and that dN/dt decreases more in the case of exponential growth than the logistic or Gompertz cases as the tumour shrinks. Consequently, as the tumour shrinks, the repopulation rate for Gompertz and logistic kinetics increases to a higher level than the exponential rate, resulting in a less effective reduction in the tumour as treatment continues. Table 1 details the outcome from the three growth laws given a uniform treatment schedule, i.e. a daily dose of 2 Gy for 30 consecutive days with no gaps. Tabulated are various scenarios: t 2 = 30, 60 or 90 days, α/β = 1, 5 or 20 Gy to denote high, medium and low repair capabilities of the cell line. The radiobiological parameter α has been taken as α = 0.2 Gy −1 (Wheldon et al 1977, Hall and Giaccia 2006) . Additionally, the two scenarios of a smaller and larger tumour volume on the commencement of treatment were considered by taking N 0 = 0.1K and 0.5K, respectively.
Uniform fractionation
Comparing the outcomes from these scenarios, both the exponential and logistic growth laws produce SFs of the same orders of magnitude. Although these do not in general alter much with variation of t 2 and N 0 /K, the α/β ratio is of importance. However, given a Gompertz style of growth, all these parameters have an impact. In general, the SF from Gompertz growth is of orders of magnitude greater than that obtained from exponential or logistic growth. Indeed, the smaller t 2 and the greater the ratio of N 0 /K, the greater the difference in orders of magnitude becomes. For high repair and larger tumour volume, there is 10 2 , 10 3 and 10 6 of difference for t 2 of 90, 60 and 30 days respectively, but decreases to 10 1 -10 2 for smaller tumour volumes. For low repair and smaller tumour volumes, the Gompertz results are almost comparable to the exponential and logistic cases. In fact, a factor of 10 1 is still apparent for larger tumour volumes. In the case that α/β = 5 Gy, a factor of 10 1 exists for smaller tumours and 10 2 for larger tumours. This may not seem much given that the final SF is significantly reduced, however, given the number of tumour cells involved, an order of magnitude or two has a considerable impact on the re-growth capacity of the tumour. Overall from table 1, it is evident that tumours which are well represented by the Gompertz law respond less well to radiotherapy than those with exponential or logistic kinetics.
Optimized uniform schedules: variation of dosage and effect on α/β ratio
In 1977 Wheldon et al designed an optimal radiotherapy schedule for tumour cells following exponential linear-quadratic survival curves and exponential repopulation kinetics. The schedule involved optimizing the dosage, uniform time interval between treatments and the number of consecutive treatments, and at the same time minimizing the damage to healthy connective tissue. In table 2, we have considered the optimum uniform schedule for exponential repopulation kinetics of Wheldon et al (1977) and noted the impact this choice of parameters has upon the case of logistic and Gompertz growth kinetics. The values taken for the optimum schedule in table 2 are α/β = 5 Gy and the optimum dose is 2.308 Gy. Considering this treatment schedule, for t 2 = 30 days, a SF of magnitude 10 −9 results, and for 60 and 90 days, a SF of 10 −11 is achieved given exponential growth. In contrast, with logistic growth the SF is 10 1 -10 3 larger, and in the case of Gompertz growth, this increases to 10 4 -10 9 larger. Once more, when the tumour is larger in volume, a greater difference in the magnitude of the SF is apparent, but in this treatment schedule, the larger t 2 is, the greater the deviation of the SF from that obtained by considering exponential growth.
Therefore, using this optimized treatment schedule for the exponential growth causes a greater variation in the outcome if other growth mechanisms were actually taking place rather than the assumed exponential re-growth. In particular, the Gompertz law results in a significantly higher proportion of clonogenic cells surviving radiotherapy compared with the exponential and logistic laws. This difference is more pronounced in the optimum treatment schedule compared with the uniform treatment tabulated in table 1.
Standardized fractionation
All four growth models have all been appropriately scaled to mimic the initial growth of one another, as depicted in figure 1. The growth curves are essentially the same for 25 or more days in the case of a fast growth rate (t 2 = 30 days), with even better agreement for slower growing tumours. Even so, differences in the SF have still emerged for uniform fractionation, as tabulated in table 1, and are even more apparent for standardized fractionation, the results of which are presented in table 3. Standardized fractionation is frequently employed as it allows the patient to rest and return home for the weekend as well as reducing overheads in the employment of staff.
Once again, the SF given exponential and logistic re-growth are comparable, though at times a difference of a factor of 10 1 can arise. Thus, by this alternative nonlinear mechanism of growth with rest periods at the weekend, variations in the SF become more noticeable. Comparing the result obtained given exponential growth and Gompertz growth, there is a factor of 10 0 -10 7 in the SF larger for Gompertz growth. The largest difference of 10 7 , 10 4 and 10 3 occurs with high repair capacity and large tumour volume with t 2 being 30, 60 and 90 days, respectively. With a smaller tumour volume the difference between the SF given exponential and Gompertz growth is less, but still significant at 10 1 -10 3 . As the repair capacity decreases, so too does the magnitude of difference, though a difference still occurs by a variation in the style of re-growth of the tumour.
Accelerated fractionation
Lastly, consideration was given to accelerated fractionated treatment schedules in which the dosage and total time period of treatment is the same, but a greater number of treatments occurs. That is, two treatments can be given in one day, the second being 6 hours (or more) after the first. Such treatment schedules are implemented for low repair tumours, such as in the case of advanced head and neck cancer (O'Sullivan et al 2002) . Tables 4 and 5 are the results obtained for an accelerated fractionation of 33 treatments in 31 days, with treatments occurring on weekdays with additional treatments on Tuesday and Thursdays. Table 4 documents the results achieved when a dose of 2 Gy is given, whilst table 5 is for D = 1.8 Gy.
In table 4, for exponential or logistic growth kinetics, the outcome is to the same order of magnitude in all but one case where a factor 10 1 exists. For tumours with a Gompertz style of growth, a factor of 10 0 -10 2 emerges. This corresponds to a significant number of tumour cells surviving which can then proliferate allowing re-growth of the tumour. Table 5 outlines the results for a dose of 1.8 Gys in which effects of toxicity in patient treatment have been reduced compared to the schedule in table 4 (O'Sullivan et al 2002) . Comparison of the various growth mechanisms again follows the same form as for D = 2 Gy, though it must be noted that the reduction in dosage has also reduced the effectiveness in reducing the tumour by an order of magnitude. This is often the delicate balance that radiotherapists are forced to make between maximizing damage to the tumour while at the same time minimizing damage to surrounding healthy tissue. That is, implementation of a treatment schedule requires quantitative radiobiological modelling of the response to fractionated radiation of both the tumour and normal tissue, together with clinical expertise of what constitutes the acceptable level of toxicity to the normal tissues affected. In both cases considered here, the results in tables 4 and 5 indicate that a tumour with a low repair capacity which follows Gompertzian rather than logistic or exponential repopulation kinetics has a poorer prognosis for tumour eradication.
Comparing the results illustrated in figures 2(a) and (b), it is clear that a tumour with a low value of α/β and standardized fractionation responds better to treatment than a tumour with a high value of α/β, accelerated fractionation and lower dose, despite the extra treatments given for the tumour with the higher value of α/β. Comparing SFs from tables 3, 4 and 5 for α/β = 20 Gy, the choice of fractionation schedule and dose are of key importance. In tables 3 and 4, where the fractionation scheme is changed from standardized to accelerated, an improvement of one order of magnitude is achieved on the whole. This is more apparent for exponential and logistic growth kinetics than Gompertzian growth, where less improvement in the eradication of the tumour results. By decreasing the dosage from 2 to 1.8 Gy, the improvement achieved from the accelerated treatment plan is diminished, back to levels comparable to standardized fractionation at the higher dose of 2 Gy.
Conclusions
Linear and nonlinear representations of growth kinetics of a tumour have been considered within the LQ model for radiotherapy treatment. Appropriate scaling of the growth kinetics was carried out at commencement of treatment. The impact on the SF was investigated over a range of scenarios and treatment schedules. The resulting SFs were presented given uniform, optimized uniform, standardized and accelerated treatment schedules. The radiobiological ratio α/β = 1, 5, 20 Gy was taken as is appropriate for cell lines with high, medium and low repair capacities, such as 1 Gy for prostate cancer and 20 Gy for advanced head and neck cancer. Additionally, smaller and larger tumour volumes at the commencement of treatment were considered by taking N 0 = 0.1K and 0.5K. Variation in the tumour doubling time t 2 and the dose D was also included.
Calculations based on the present analysis indicate that variation in SF to orders of magnitude emerge depending on the form of growth kinetics. Logistic and exponential growth models for tumour re-growth between treatments produced similar results but the Gompertz growth model has been shown to result in significantly less tumour eradication. Many cancers have been shown to follow Gompertzian growth in the early stages, and our study shows that the growth law the tumour follows has a significant effect on the outcome of the survival of the clonogenic cells in radiotherapy. Overall, the higher the repair capacity of the cell line, the greater the difference in the SF becomes on comparison to the SF given exponential growth.
This factor could have a profound effect on the tumour's ability to regrow given the number of extra surviving cells that can proliferate. Over the various treatment schedules, it was found that those with gaps in the treatment allow for the larger variation in outcome of the SF to occur. However, with the accelerated treatment schedule, these variations where reduced. Nonetheless, one to two orders of magnitude were still apparent in the SF to that of the SF from exponential re-growth. Therefore, whether gaps in treatment schedules are planned or unplanned, the greater the variation in the outcome of a treatment schedule can become given a limited form of growth for the tumour, rather than exponential. Lastly, it must be emphasized that calculations of this sort can act only as a guide, and do not replace clinical judgement. However, it is useful to understand and observe the impact that the mechanism of re-growth can have on the final outcome for a patient and that it is indeed another variable to be deliberated upon in the implementation of treatment schedules.
A future direction of this study would be the incorporation of non-constant growth kinetics in LQ models adapted for heterogenous tumour geometry. Hypoxic zones are noted to be more radio-resistant than well oxygenated areas, therefore they are harder to eradicate. Likewise, low oxygenated areas will have a lower proliferation rate, or be quiescent. The impact of sub-populations of a tumour along with non-constant growth kinetics would be interesting to study to answer questions such as, will hypoxia increase or decrease the effectiveness of radiotherapy? How effective is accelerated fractionation compared to standard fractionation on heterogeneous tumours. Does the level of heterogeneity of the tumour matter? These questions will be addressed in future work.
